Angiotensin (1-7) vs BPC-157 — Peptide Comparison

Angiotensin (1-7) vs BPC-157 — Peptide Comparison Angiotensin (1-7) vs BPC-157 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Angiotensin (1-7) 0.5-1 mcg/kg–5-10 mcg/kg mcg BPC-157 250–500 mcg Frequency Once daily Administration As directed by healthcare provider Subcutaneous injection Cycle Length Ongoing/indefinite 4-6 weeks Onset Speed Moderate (1-2 weeks) Evidence Level Moderate human trials (Phase 1-2) Strong preclinical (extensive animal studies) Efficacy Heart Health & Protection Blood Pressure Balance Anti-Inflammatory Support Primary Benefit Secondary Benefit Additional Benefit Technical Data Molecular Formula C41H62N12O11 Molecular Weight 899.02 g/mol Half-Life Approximately 2-6 hours (varies by route of administration) Bioavailability Varies by route of administration CAS Number 25016-41-7 C62H98N16O22 1419.53 g/mol 4-6 hours ~100% (subcutaneous) 137525-51-0 Protocols standard 100 mcg/kg Once daily after each chemotherapy session Up to 6 chemotherapy cycles In a cancer trial, this dose was injected under the skin after chemo to help protect platelet counts. A higher 300 mcg/kg dose was also tested but did not work better. [4] 0.5 mg/kg Up to 10 days In a COVID-19 study, the lab-made form (called TXA-127) was given as a daily drip into a vein. No serious drug-related side effects were seen. [5] starting 250 mcg 1-2 weeks A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2]. 250-500 mcg Twice daily Commonly used range for tissue and tendon recovery in research practice [1][3]. advanced 500 mcg 6-8 weeks Upper end used in practice for more demanding acute injuries [1][3]. Applications Cardiovascular health and heart protection Angiotensin (1-7) is particularly well-suited for individuals focused on cardiovascular health and heart protection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Blood pressure management and hypertension Angiotensin (1-7) is particularly well-suited for individuals focused on blood pressure management and hypertension. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Recovery from heart-related conditions Angiotensin (1-7) is particularly well-suited for individuals focused on recovery from heart-related conditions. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Anti-inflammatory support Angiotensin (1-7) is particularly well-suited for individuals focused on anti-inflammatory support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Tendon and ligament injuries Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair Gut healing IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue Muscle injuries Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression Joint problems Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties Post-surgical recovery Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms Safety Profile Common Hypotension (Low Blood Pressure) Dizziness or Lightheadedness Injection Site Reactions Headache Serious Hyperkalemia (High Potassium) Injection site redness Mild nausea Dizziness Uncommon Fatigue Hot/cold sensations Allergic reaction Research Status FDA Status Research compound Safety Overview Angiotensin (1-7) is not FDA-approved and has no completed human clinical trials, with all safety data limited to animal studies and in vitro mechanistic work. Animal studies suggest potential benefits in hypertension and cardiac remodeling but also reveal risks of hypotension, particularly with concurrent ACE inhibitor or ARB therapy. The peptide's effects on systemic inflammation and immune function in animal models are not validated in humans. No pharmacokinetic data exists defining safe doses, optimal delivery routes, or organ accumulation patterns in humans. Contraindications xSevere hypotension or uncontrolled low blood pressure xAcute myocardial infarction in early stages xConcurrent use with certain ACE inhibitors without medical supervision xPregnancy and breastfeeding (insufficient safety data) BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions. xPregnancy xBreastfeeding xActive cancer xHistory of cancer Decision Guide Choose Angiotensin (1-7) if... Cardiovascular health and heart protection Blood pressure management and hypertension Recovery from heart-related conditions Anti-inflammatory support Choose BPC-157 if... Injury recovery Post-surgery healing Chronic pain management Gut health